Mesa Laboratories, Inc. $MLAB Holdings Raised by Diamond Hill Capital Management Inc.

Diamond Hill Capital Management Inc. raised its position in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 218.0% in the third quarter, Holdings Channel.com reports. The institutional investor owned 123,381 shares of the medical instruments supplier’s stock after buying an additional 84,582 shares during the period. Diamond Hill Capital Management Inc.’s holdings in Mesa Laboratories were worth $8,268,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of MLAB. CWM LLC boosted its position in Mesa Laboratories by 48.9% during the 3rd quarter. CWM LLC now owns 597 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 196 shares during the period. Farther Finance Advisors LLC increased its holdings in Mesa Laboratories by 17,733.3% in the third quarter. Farther Finance Advisors LLC now owns 535 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 532 shares during the last quarter. Texas Permanent School Fund Corp raised its holdings in shares of Mesa Laboratories by 37.6% during the 2nd quarter. Texas Permanent School Fund Corp now owns 3,301 shares of the medical instruments supplier’s stock valued at $311,000 after purchasing an additional 902 shares in the last quarter. Public Sector Pension Investment Board boosted its holdings in Mesa Laboratories by 7.4% in the second quarter. Public Sector Pension Investment Board now owns 18,528 shares of the medical instruments supplier’s stock worth $1,746,000 after purchasing an additional 1,272 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in Mesa Laboratories by 432.9% during the second quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock valued at $79,000 after buying an additional 684 shares in the last quarter. Hedge funds and other institutional investors own 90.60% of the company’s stock.

Analyst Upgrades and Downgrades

MLAB has been the subject of a number of recent analyst reports. Wall Street Zen raised Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Mesa Laboratories in a research report on Thursday, January 22nd. Wells Fargo & Company boosted their price target on Mesa Laboratories from $83.00 to $94.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 4th. Finally, Zacks Research upgraded Mesa Laboratories from a “strong sell” rating to a “hold” rating in a research report on Friday, January 9th. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $94.00.

Mesa Laboratories Stock Performance

Shares of NASDAQ:MLAB opened at $93.27 on Monday. The business’s fifty day moving average price is $82.11 and its two-hundred day moving average price is $74.93. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.94 and a quick ratio of 1.45. Mesa Laboratories, Inc. has a fifty-two week low of $55.45 and a fifty-two week high of $155.12. The stock has a market capitalization of $514.85 million, a price-to-earnings ratio of 145.74 and a beta of 0.89.

Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings data on Tuesday, February 3rd. The medical instruments supplier reported $3.07 earnings per share for the quarter, topping the consensus estimate of $2.41 by $0.66. Mesa Laboratories had a net margin of 1.51% and a return on equity of 22.02%. The firm had revenue of $65.13 million for the quarter, compared to analysts’ expectations of $63.23 million. As a group, analysts predict that Mesa Laboratories, Inc. will post 8 EPS for the current fiscal year.

Mesa Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 16th. Shareholders of record on Saturday, February 28th will be issued a $0.16 dividend. The ex-dividend date of this dividend is Friday, February 27th. This represents a $0.64 dividend on an annualized basis and a yield of 0.7%. Mesa Laboratories’s payout ratio is currently 100.00%.

Mesa Laboratories Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.